Sign in

CDTX on NASDAQ

Cidara Therapeutics

Logo: cidara.com4

In its 2025 annual report the company says: “We are a biotechnology company using our proprietary Cloudbreak ® platform to develop drug-Fc conjugate, or DFC, immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. Our lead clinical-stage asset is CD388, a DFC intended for influenza prophylaxis, which we discovered and advanced to the clinic under a partnership with J&J Innovative Medicine, previously Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, or Janssen.”6 It was founded in 2013.1 It is headquartered in San Diego.1 Its shares trade on NASDAQ under the symbol CDTX.1

Price unavailable

Last updated Oct 21, 2026.

Overview

2013Founded1

Compare with Inhibrx Biosciences, Inc., Scinai Immunotherapeutics Ltd. or SAB Biotherapeutics, Inc., or pick any stock.

  • TickerCDTX on NASDAQ1
  • Industrypharmaceutical industry1
  • HeadquartersSan Diego1
  • Websitewww.cidara.com
  • Legal formDelaware corporation1
  • Incorporated inDE5
  • Business address6310 Nancy Ridge Drive, Suite 101, San Diego, Ca 921215
  • Filer categoryNon-accelerated filer, Smaller reporting company5
  • LEI549300IHQ9Z7RI1X2D223
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States3
  • Registered withDivision of Corporations, Department of State, 52513633

See how the biggest companies compare on our leaderboards

Cidara Therapeutics image from its website
Image: cidara.com4

We are a biotechnology company using our proprietary Cloudbreak ® platform to develop drug-Fc conjugate, or DFC, immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases.6 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

-13811.9%Operating margin7
-13319.8%Net margin7
-70.6%Revenue growth, 20247
-104.0%Return on equity7
-$176.7MFree cash flow7

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Research and development100¢$71.9M

Out of $1.3M in revenue.7 The company lost money this year.

Financial statements

Revenue87$1.3M in 2024
0$2.0M$4.0M$6.0M2022: $0$020222023: $4.3M$4.3M20232024: $1.3M$1.3M2024−71%
Operating income9101187-$176.1M in 2024+178% since 2018
-$200.0M-$150.0M-$100.0M-$50.0M02018: -$63.3M-$63.3M20182019: -$41.7M-$41.7M2019−34%2020: -$71.8M-$71.8M2020+72%2021: -$42.3M-$42.3M2021−41%2022: -$33.5M-$33.5M2022−21%2023: -$27.1M-$27.1M2023−19%2024: -$176.1M-$176.1M2024+551%
Net income9101187-$169.8M in 2024+188% since 2018
-$200.0M-$150.0M-$100.0M-$50.0M02018: -$59.0M-$59.0M20182019: -$41.1M-$41.1M2019−30%2020: -$72.1M-$72.1M2020+75%2021: -$42.5M-$42.5M2021−41%2022: -$33.6M-$33.6M2022−21%2023: -$22.9M-$22.9M2023−32%2024: -$169.8M-$169.8M2024+641%
Fiscal year2018201920202021202220232024
Revenue$08$4.3M8$1.3M7
Research and development$49.1M9$46.4M10$68.0M11$73.1M11$77.4M8$36.8M7$71.9M7
Selling, general and admin$20.5M8$18.3M8
Operating expenses$91.8M11$98.0M8$50.3M7$177.4M7
Operating income-$63.3M9-$41.7M10-$71.8M11-$42.3M11-$33.5M8-$27.1M7-$176.1M7
Income before tax-$42.5M11-$33.3M8-$25.1M7-$170.3M7
Income tax$09$010$011$011$272.0K8$15.0K7$07
Net income-$59.0M9-$41.1M10-$72.1M11-$42.5M11-$33.6M8-$22.9M7-$169.8M7
Earnings per share-$1.3710-$1.8011-$0.8111-$0.488-$5.257-$26.757
Earnings per share (diluted)-$1.3710-$1.8011-$0.8111-$0.488-$5.257-$26.757
Shares (weighted, basic)69.9M shares84.4M shares76.3M shares7
Shares (weighted, diluted)52.5M shares1169.9M shares84.4M shares76.3M shares7

Compare Cidara Therapeutics with another company

Corporate structure

Cidara Therapeutics sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Cidara Therapeutics

  • Cidara Therapeutics San Diego, California, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Cidara Therapeutics reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$3.9M7 Dec 31, 2024$3.7M7 Dec 31, 2023+3.1%
Accumulated depreciation$3.3M7 Dec 31, 2024$3.2M7 Dec 31, 2023+4.8%
Property and equipment, net$521.0K7 Dec 31, 2024$557.0K7 Dec 31, 2023−6.5%
Finance-lease assets$703.0K7 Dec 31, 2024$782.0K7 Dec 31, 2023−10.1%
Operating-lease assets (leased space)$2.7M7 Dec 31, 2024$3.8M7 Dec 31, 2023−27.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$189.8M7 Dec 31, 2024$35.8M7 Dec 31, 2023+430.6%

Inventory

ItemLatestA year beforeChange
Inventory, total$6.1M8 Dec 31, 2023$08 Dec 31, 2022
Raw materials$2.7M8 Dec 31, 2023$08 Dec 31, 2022
Work in process$3.4M8 Dec 31, 2023$08 Dec 31, 2022
Finished goods$08 Dec 31, 2023$08 Dec 31, 2022

Properties, in its own words

We lease a 29,638 square foot facility in San Diego, California for administrative, research and development activities. Our lease expires in December 2026, subject to our option to renew for up to two additional two-year terms. We believe that our facility is sufficient to meet our needs and that suitable additional space will be available as and when needed.

Item 2 of the 10-K filed Mar 6, 2025.6

Leadership

Who has led Cidara Therapeutics, and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. Kevin Forrest2015–2016
  2. Matthew Onaitis2016–2018
  3. James E. Levine2018–2021
  4. Preetam Shah2021–2025
  5. Frank Karbe2025–now

Chief operating officer

  1. Kevin Forrest2015–2016
  2. Paul Daruwala2018–2022
  3. Shane Ward2023–now
201520202025
Board members and other officers (30)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Officer, DirectorJeffrey Stein, Ph.D. named May 6, 202451
  • Executive OfficerLeslie R. Tari, Ph.D. named May 6, 202451
  • Executive OfficerPreetam R. Shah, Ph.D. named May 6, 202451
  • DirectorBonnie R. Bassler, Ph.D. named May 6, 202451
  • DirectorJames R. Merson, Ph.D. named May 6, 202451
  • DirectorLaura R. Tadvalkar, Ph.D. named May 6, 202451

Former names

  • K2 THERAPEUTICS, INC.Jun 17, 2014 to Feb 4, 20155

Timeline

  1. Jan 7, 20268-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer52
  2. Nov 14, 20258-K Entered a material agreement; Regulation FD disclosure53
  3. Nov 6, 20258-K Results of operations54
  4. Oct 6, 20258-K Entered a material agreement55
  5. Sep 24, 20258-K Other events56
  6. Aug 7, 20258-K Results of operations57
  7. Jun 25, 20258-K Other events58
  8. Jun 24, 20258-K Other events59
  9. Jun 23, 20258-K Other events60
  10. Jun 20, 20258-K Executive or director change; Bylaws or fiscal year changed; Shareholder vote61
  11. May 8, 20258-K Results of operations62
  12. Mar 6, 20258-K Results of operations63
  13. 2013Founded Founded1

Calendar

When it reported results

  1. Nov 6, 2025Reported quarterly or annual results54
  2. Aug 7, 2025Reported quarterly or annual results57
  3. May 8, 2025Reported quarterly or annual results62
  4. Mar 6, 2025Reported quarterly or annual results63
  5. Nov 7, 2024Reported quarterly or annual results64
  6. Aug 13, 2024Reported quarterly or annual results65
  7. May 15, 2024Reported quarterly or annual results66
  8. Apr 22, 2024Reported quarterly or annual results67

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

363 filings to the SEC since October 2021: 4 annual reports, 13 quarterly reports, 61 major events, 140 insider forms, 52 large holders, 1 private raises, 92 other. The latest 20:

  1. Feb 17, 2026SCHEDULE 13G/A EDGAR
  2. Feb 17, 2026SCHEDULE 13G/A EDGAR
  3. Feb 13, 2026SCHEDULE 13G/A EDGAR
  4. Jan 30, 2026SCHEDULE 13G EDGAR
  5. Jan 20, 202615-12G EDGAR
  6. Jan 9, 2026EFFECT EDGAR
  7. Jan 9, 2026EFFECT EDGAR
  8. Jan 9, 2026EFFECT EDGAR
  9. Jan 9, 2026EFFECT EDGAR
  10. Jan 9, 2026EFFECT EDGAR
  11. Jan 9, 2026EFFECT EDGAR
  12. Jan 9, 2026SCHEDULE 13D/A EDGAR
  13. Jan 9, 20264 EDGAR
  14. Jan 7, 20264 EDGAR
  15. Jan 7, 20264 EDGAR
  16. Jan 7, 20264 EDGAR
  17. Jan 7, 20264 EDGAR
  18. Jan 7, 20264 EDGAR
  19. Jan 7, 20264 EDGAR
  20. Jan 7, 20264 EDGAR

The 363 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

35 open-market trades by officers, directors and large owners since October 2021: 9 buys and 26 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 10, 2025Ward ShaneCOO & CLOSale9,959$220.08$2.2MForm 4
Sep 11, 2025Davarpanah Nicole NegarChief Medical OfficerSale474$62.86$29.8KForm 4
Jun 26, 2025Kolchinsky PeterDirectorBuy2,272,727$44.00$100.0MForm 4
Jun 3, 2025Mineo ChrysaDirectorBuy1,050$23.44$24.6KForm 4
Jun 2, 2025Mineo ChrysaDirectorBuy2,270$21.71$49.3KForm 4
Mar 11, 2025Ward ShaneCOO & CLOSale1,664$21.96$36.5KForm 4
Mar 11, 2025Tari LeslieCHIEF SCIENTIFIC OFFICERSale1,773$21.96$38.9KForm 4
Sep 11, 2024Sandison TaylorChief Medical OfficerSale924$11.64$10.8KForm 4
Sep 11, 2024Tari LeslieCHIEF SCIENTIFIC OFFICERSale909$11.64$10.6KForm 4
Jun 7, 2024Stein JeffreyPresident & CEOBuy8,000$13.21$105.7KForm 4
Mar 11, 2024Tari LeslieCHIEF SCIENTIFIC OFFICERSale21,029$0.67$14.1KForm 4
Mar 11, 2024Sandison TaylorChief Medical OfficerSale20,662$0.67$13.8KForm 4
Mar 11, 2024Ward ShaneCOO & CLOSale20,473$0.67$13.7KForm 4
Mar 11, 2024Shah PreetamChief Financial OfficerSale18,931$0.67$12.7KForm 4
Sep 11, 2023Tari LeslieCHIEF SCIENTIFIC OFFICERSale18,469$0.95$17.5KForm 4
Sep 11, 2023Sandison TaylorChief Medical OfficerSale18,793$0.95$17.9KForm 4
Aug 14, 2023Tari LeslieCHIEF SCIENTIFIC OFFICERBuy10,000$0.97$9.7KForm 4
Aug 8, 2023Stein JeffreyPresident & CEOBuy50,000$0.96$48.0KForm 4
Mar 27, 2023Stein JeffreyPresident & CEOBuy50,000$1.04$52.0KForm 4
Mar 13, 2023Ward ShaneCOO & CLOSale4,329$1.53$6.6KForm 4

All 35 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2024Jeffrey Stein, Ph.D.President and Chief Executive Officer$617.6K$6.0M85
2024Leslie Tari, Ph.D.Chief Scientific Officer$453.5K$2.0M85
2024Taylor Sandison, M.D., M.P.H.Former Chief Medical Officer$505.1K$2.0M85
2023Jeffrey Stein, Ph.D.President and Chief Executive Officer$593.8K$1.6M85
2023Taylor Sandison, M.D., M.P.H.Former Chief Medical Officer$487.1K$884.1K85

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Apr 24, 2024Raised $240 million in a private offering of equity Form D: 7 investors so far Form D

SEC filer profile

How Cidara Therapeutics is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCidara Therapeutics, Inc.2
  • CIK0001610618
  • Employer ID (EIN)46-15372866
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company6
  • Incorporated inDelaware6
  • Fiscal year endsDecember 312
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address6310 Nancy Ridge Drive, Suite 101, San Diego, CA 921212
  • Phone858-752-61702
  • Shares outstanding31,439,371 as of Nov 3, 202513
  • Public float$53.3M as of Jun 28, 20246
  • AuditorErnst & Young LLP, San Diego, California PCAOB ID 42; no auditor attestation of internal control over financial reporting6
  • On EDGAR sinceJun 17, 20142
  • Filings798 in all: 4 (274), 8-K (148), 3 (40), SC 13G/A (38), 10-Q (33), SC 13G (22), SCHEDULE 13G/A (21), CORRESP (19)2
    All 52 form types

    UPLOAD (18), 424B5 (16), EFFECT (16), S-8 (14), S-8 POS (14), DEF 14A (12), DEFA14A (11), 10-K (10), S-3 (8), D (7), POS AM (6), SCHEDULE 13G (6), 4/A (5), 424B3 (5), SCHEDULE 13D/A (5), 10-Q/A (4), PRE 14A (4), SC 13D/A (4), 8-K/A (3), ARS (3), S-1 (3), SC 13D (3), SC TO-T/A (3), SC 14D9/A (2), SC TO-I/A (2), 15-12G (1), 25-NSE (1), 3/A (1), 424B4 (1), 8-A12B (1), CERTNAS (1), CT ORDER (1), DRS (1), NT 10-K (1), RW (1), S-1/A (1), S-1MEF (1), S-3/A (1), S-3MEF (1), SC 14D9 (1), SC TO-C (1), SC TO-I (1), SC TO-T (1), SC14D9C (1)

  • Latest filingsAnnual report (10-K) Mar 6, 2025
    Quarterly report (10-Q) Nov 6, 2025
    Proxy statement (DEF 14A) Apr 25, 2025
    Latest 8-K (8-K) Jan 7, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.0001 Par Value“CDTX”The Nasdaq Stock Market LLC

From the cover page of the 10-K filed Mar 6, 2025 (Section 12(b) of the Exchange Act).6

Risk factors and legal proceedings

The risks Cidara Therapeutics names in Item 1A of its 10-K filed Mar 6, 2025: 59 risks under these headings, as written.6

  • Risks Related to Our Financial Position and Need for Additional Capital
  • Due to the delayed filing with the SEC of our Annual Report on Form 10-K for the year ended December 31, 2023, we are not currently eligible to use a registration statement on Form S-3 to register the offer and sale or resale of securities, which may adversely affect our ability to raise future capital.
  • We need substantial additional funding to advance CD388 beyond Phase 2b, and to advance CBO421 and our other Cloudbreak programs.
  • Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
  • We have incurred significant operating losses since our inception, and we anticipate that we will continue to incur substantial operating losses for the foreseeable future. We may never achieve or maintain profitability.
  • Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.
  • We have no history of commercializing pharmaceutical products, which may make it difficult for you to evaluate the prospect for our future viability.
  • Risks Related to Drug Discovery, Development and Commercialization
  • We depend heavily on the success of CD388, which has completed Phase 2a clinical development, and we are very early in our efforts to develop other product candidates from our Cloudbreak program, none of which may be successful.
  • If we experience delays or difficulties in enrolling patients in our clinical trials our receipt of necessary regulatory approvals could be delayed or prevented.
  • If clinical trials for CD388 or any other product candidates are delayed, terminated or suspended, or fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities, we may incur additional costs, or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.
  • If serious adverse reactions or unexpected characteristics of our product candidates are identified during development, we may need to abandon or limit our development of some or all of our product candidates.
The other 49 risks
  • Any of our product candidates that receive marketing approval may fail to achieve the degree of market acceptance by physicians, patients, formulary committees, third-party payors and others in the medical community necessary for commercial success.
  • If, in the future, we are unable to establish sales and marketing capabilities or to selectively enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates, if and when they are approved. In addition, if we enter into agreements with third parties to sell and market our product candidates, such third parties may not be successful in commercializing our products.
  • We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.
  • Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • Even if we are able to commercialize any product candidates, these products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business.
  • Product liability lawsuits against us could cause us to incur substantial liabilities and could limit the commercialization of any product candidates we may develop.
  • If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.
  • We may not be successful in our efforts to identify, discover, and develop potential product candidates through our Cloudbreak platform or otherwise.
  • Risks Related to Our Dependence on Third Parties
  • We may seek to selectively establish collaborations and, if we are unable to establish them on commercially reasonable terms or at all, we may have to alter our research, clinical development and commercialization plans.
  • We intend to continue to rely on third parties to conduct our clinical trials and to conduct some aspects of our research and preclinical testing and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing.
  • We have no experience manufacturing product candidates on a clinical or commercial scale and will be dependent on third parties for the manufacture of our product candidates. If we experience problems with any of these third parties, they could delay clinical development or marketing approval of our product candidates or our ability to sell any approved products.
  • Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters
  • If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing, our product candidates and our ability to generate revenue will be impaired.
  • Any product candidate for which we obtain marketing approval could be subject to marketing restrictions or withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products.
  • Our relationships with customers, health care professionals and third-party payors may be subject to applicable healthcare laws, which could expose us to penalties, including administrative, civil or criminal penalties, damages, fines, imprisonment, exclusion from participation in federal healthcare programs such as Medicare and Medicaid, reputational harm, the curtailment or restructuring of our operations and diminished future profits and earnings.
  • If our information technology systems, or those of third parties with whom we work, or our data are or were compromised, we could experience adverse consequences resulting from such compromise, including, but not limited to, regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences.
  • We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.
  • The pharmaceutical industry in China is highly regulated and such regulations are subject to change which may affect approval and commercialization of our drugs.
  • Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.
  • Risks Related to Our Intellectual Property
  • If our efforts to protect the proprietary nature of the intellectual property related to CD388, CBO421, our other Cloudbreak compounds or our other product candidates or compounds are not adequate, we may not be able to compete effectively in our markets.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • Third-party claims of intellectual property infringement may prevent or delay our drug discovery and development efforts.
  • We may be required to file lawsuits or take other actions to protect or enforce our patents, which could be expensive, time consuming and unsuccessful.
  • Issued patents covering our product candidates and technologies could be found invalid or unenforceable if challenged in court or the USPTO.
  • Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.
  • We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.
  • If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
  • We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
  • Risks Related to U.S. Government Contracts and Grants
  • If we are unable to generate revenues from partnerships, government funding or other sources of funding, we may be unable to resume our preclinical Cloudbreak programs.
  • Our use of government funding adds uncertainty to our research and commercialization efforts and may impose requirements that increase our costs.
  • Changes in funding for the FDA, the SEC, and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.
  • Laws and regulations affecting government contracts make it more expensive and difficult for us to successfully conduct our business.
  • Risks Related to Employee Matters and Managing Growth
  • Our future success depends on our ability to retain our senior management team and to attract, retain and motivate qualified personnel.
  • We expect to expand our operations, and may encounter difficulties in managing our growth, which could disrupt our business.
  • Risks Related to Ownership of our Common Stock
  • The price of our stock may be volatile, and you could lose all or part of your investment.
  • Our principal stockholders and management own a significant percentage of our stock and are able to exert significant influence over matters subject to stockholder approval.
  • If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate financial statements on a timely basis could be impaired and our public reporting may be unreliable.
  • We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock.
  • We incur significant costs as a result of operating as a public company, and our management devotes substantial time to compliance initiatives.
  • Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.
  • Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, through the conversion of our Series A Convertible Voting Preferred Stock and Series X Convertible Preferred Stock, or through exercise of warrants and pre-funded warrants, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.
  • We have broad discretion in the use of working capital and may not use it effectively.
  • Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.
  • Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
  • If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.
  • Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
  • Uncertainties in the interpretation and application of existing, new and proposed tax laws and regulations could materially affect our tax obligations and effective tax rate.
  • Our business and operations would suffer in the event of system failures.
  • Our operations are vulnerable to interruption by natural disasters, power loss, terrorist activity, public health crisis, pandemic diseases and other events beyond our control, the occurrence of which could materially harm our business.

Legal proceedings

From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

The opening of Item 3, Legal Proceedings.6

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
    SEC EDGAROther events
  57. 57
  58. 58
    SEC EDGAROther events
  59. 59
    SEC EDGAROther events
  60. 60
    SEC EDGAROther events
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85